{"id":"cggv:73ed48ac-bdd6-4608-953d-773da6ade759v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:73ed48ac-bdd6-4608-953d-773da6ade759_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10072","date":"2023-11-02T16:00:00.000Z","role":"Approver"},{"id":"cggv:73ed48ac-bdd6-4608-953d-773da6ade759_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10072","date":"2024-01-01T23:54:39.818Z","role":"Publisher"}],"curationReasons":{"id":"cg:NewCuration"},"earliestArticle":{"id":"https://pubmed.ncbi.nlm.nih.gov/19615668","type":"dc:BibliographicResource","dc:abstract":"Cone photoreceptor disorders form a clinical spectrum of diseases that include progressive cone dystrophy (CD) and complete and incomplete achromatopsia (ACHM). The underlying disease mechanisms of autosomal recessive (ar)CD are largely unknown. Our aim was to identify causative genes for these disorders by genome-wide homozygosity mapping. We investigated 75 ACHM, 97 arCD, and 20 early-onset arCD probands and excluded the involvement of known genes for ACHM and arCD. Subsequently, we performed high-resolution SNP analysis and identified large homozygous regions spanning the PDE6C gene in one sibling pair with early-onset arCD and one sibling pair with incomplete ACHM. The PDE6C gene encodes the cone alpha subunit of cyclic guanosine monophosphate (cGMP) phosphodiesterase, which converts cGMP to 5'-GMP, and thereby plays an essential role in cone phototransduction. Sequence analysis of the coding region of PDE6C revealed homozygous missense mutations (p.R29W, p.Y323N) in both sibling pairs. Sequence analysis of 104 probands with arCD and 10 probands with ACHM revealed compound heterozygous PDE6C mutations in three complete ACHM patients from two families. One patient had a frameshift mutation and a splice defect; the other two had a splice defect and a missense variant (p.M455V). Cross-sectional retinal imaging via optical coherence tomography revealed a more pronounced absence of cone photoreceptors in patients with ACHM compared to patients with early-onset arCD. Our findings identify PDE6C as a gene for cone photoreceptor disorders and show that arCD and ACHM constitute genetically and clinically overlapping phenotypes.","dc:creator":"Thiadens AA","dc:date":"2009","dc:title":"Homozygosity mapping reveals PDE6C mutations in patients with early-onset cone photoreceptor disorders."},"evidence":[{"id":"cggv:73ed48ac-bdd6-4608-953d-773da6ade759_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:73ed48ac-bdd6-4608-953d-773da6ade759_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:106c290b-66a1-4a0c-821c-35b61910f769","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:b5216c14-100d-4311-8c17-e346392ac804","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"Transcriptomic profiling of more than 70 human tissues shows that retinal tissues exhibit the highest levels of PDE6C mRNA (https://eyeintegration.nei.nih.gov/).","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/30239781","type":"dc:BibliographicResource","dc:abstract":"The human eye is built from several specialized tissues which direct, capture and pre-process information to provide vision. The gene expression of the different eye tissues has been extensively profiled with RNA-seq across numerous studies. Large consortium projects have also used RNA-seq to study gene expression patterning across many different human tissues, minus the eye. There has not been an integrated study of expression patterns from multiple eye tissues compared with other human body tissues. We have collated all publicly available healthy human eye RNA-seq datasets as well as dozens of other tissues. We use this fully integrated dataset to probe the biological processes and pan expression relationships between the cornea, retina, retinal pigment epithelium (RPE)-choroid complex, and the rest of the human tissues with differential expression, clustering and gene ontology term enrichment tools. We also leverage our large collection of retina and RPE-choroid tissues to build the first human weighted gene correlation networks and use them to highlight known biological pathways and eye gene disease enrichment. We also have integrated publicly available single-cell RNA-seq data from mouse retina into our framework for validation and discovery. Finally, we make all these data, analyses and visualizations available via a powerful interactive web application (https://eyeintegration.nei.nih.gov/).","dc:creator":"Bryan JM","dc:date":"2018","dc:title":"Identifying core biological processes distinguishing human eye tissues with precise systems-level gene expression analyses and weighted correlation networks."},"rdfs:label":"PDE6C mRNA levels are highest in retinal tissues."}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5,"dc:description":"Default scoring is considered appropriate, as PDE6C appears to be highly specifically expressed in retinal tissues."},{"id":"cggv:2eb48481-1a18-4629-8eda-f2daf2208a0b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:9fb27183-9083-4630-93e1-6197e1627315","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionA"},"dc:description":"PDE6A similarly encodes a cGMP phosphodiesterase but is associated specifically with rod photoreceptor cells (PMID: 20940301).","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/19801642","type":"dc:BibliographicResource","dc:abstract":"PDE6 (phosphodiesterase-6) is the effector molecule in the vertebrate phototransduction cascade. Progress in understanding the structure and function of PDE6 has been hindered by lack of an expression system of the enzyme. Here we report ectopic expression and analysis of compartmentalization and membrane dynamics of the enhanced green fluorescent protein (EGFP) fusion protein of human cone PDE6C in rods of transgenic Xenopus laevis. EGFP-PDE6C is correctly targeted to the rod outer segments in transgenic Xenopus, where it displayed a characteristic striated pattern of EGFP fluorescence. Immunofluorescence labeling indicated significant and light-independent co-localization of EGFP-PDE6C with the disc rim marker peripherin-2 and endogenous frog PDE6. The diffusion of EGFP-PDE6C on disc membranes investigated with fluorescence recovery after photobleaching was markedly slower than theoretically predicted. The enzymatic characteristics of immunoprecipitated recombinant PDE6C were similar to known properties of the native bovine PDE6C. PDE6C was potently inhibited by the cone- and rod-specific PDE6 gamma-subunits. Thus, transgenic Xenopus laevis is a unique expression system for PDE6 well suited for analysis of the mechanisms of visual diseases linked to PDE6 mutations.","dc:creator":"Muradov H","dc:date":"2009","dc:title":"Characterization of human cone phosphodiesterase-6 ectopically expressed in Xenopus laevis rods."},"rdfs:label":"PDE6C and PDE6A hydrolyze cGMP in cones and rods."}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5,"dc:description":"While PDE6C is the cone-specific cGMP hydrolase, PDE6A is the rod-specific cGMP hydrolase. Both harbor variants that cause ocular disease, although they affect different photoreceptor cell types."},{"id":"cggv:d72c1e76-95c4-4dff-9d36-c34745d451af","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:d26360c7-2208-4fd6-a3f4-6ba620835974","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"Dysfunction in a cone-specific enzyme that is part of the phototransduction cascade is consistent with the cone-specific dysfunction observed in the human patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19801642","rdfs:label":"PDE6C hydrolyzes cGMP."}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5,"dc:description":"Dysfunction in a cone-specific enzyme that is part of the phototransduction cascade is consistent with the cone-specific dysfunction observed in the human patients."}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5},{"id":"cggv:73ed48ac-bdd6-4608-953d-773da6ade759_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:de0bb9ec-7ceb-4b34-8421-5b6c909447e7","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:c2fe14c5-d55b-4963-b753-162bb09d2e6f","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"This is a naturally occurring macaque model that matches the autosomal recessive mode of inheritance from the human patients (Figure 7) and exhibits reduced visual acuity (Supplemental Video 1), lack of light-adapted ERG responses and normal dark-adapted ERG responses (Figures 1A-1E, Figure 2). The affected animals also exhibit progressive macular atrophy consistent with achromatopsia (Figure 3). Reduced foveal thickness was also observed (Figures 4A, 4B), as well as thinning of the outer nuclear layer and photoreceptor outer segments (Figures 5A, 5B).","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/30667376","type":"dc:BibliographicResource","dc:abstract":"Inherited retinal degenerations are a common cause of untreatable blindness worldwide, with retinitis pigmentosa and cone dystrophy affecting approximately 1 in 3500 and 1 in 10,000 individuals, respectively. A major limitation to the development of effective therapies is the lack of availability of animal models that fully replicate the human condition. Particularly for cone disorders, rodent, canine, and feline models with no true macula have substantive limitations. By contrast, the cone-rich macula of a nonhuman primate (NHP) closely mirrors that of the human retina. Consequently, well-defined NHP models of heritable retinal diseases, particularly cone disorders that are predictive of human conditions, are necessary to more efficiently advance new therapies for patients. We have identified 4 related NHPs at the California National Primate Research Center with visual impairment and findings from clinical ophthalmic examination, advanced retinal imaging, and electrophysiology consistent with achromatopsia. Genetic sequencing confirmed a homozygous R565Q missense mutation in the catalytic domain of PDE6C, a cone-specific phototransduction enzyme associated with achromatopsia in humans. Biochemical studies demonstrate that the mutant mRNA is translated into a stable protein that displays normal cellular localization but is unable to hydrolyze cyclic GMP (cGMP). This NHP model of a cone disorder will not only serve as a therapeutic testing ground for achromatopsia gene replacement, but also for optimization of gene editing in the macula and of cone cell replacement in general.","dc:creator":"Moshiri A","dc:date":"2019","dc:title":"A nonhuman primate model of inherited retinal disease."},"rdfs:label":"The macaque model harbors a homozygous LOF variant in PDE6C."}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":3,"dc:description":"The model has been up-scored as its phenotypes are comprehensive and represent a nearly complete match to the human patient clinical features."},{"id":"cggv:cbff89a0-50a6-489c-ac9f-ecd500092a8f","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:0aa28b2a-e5db-4256-b8e1-e142919a0659","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"This is a naturally occurring zebrafish model that matches the mode of inheritance from the human patients and exhibits lack of light-adapted ERG responses (Figures 1K, 1M) and normal dark-adapted ERG responses. The mice also exhibit rapid and progressive loss of cone photoreceptors from retinal sections (Figures 1G, 1I) and abnormal shape of the photoreceptor outer segment (Figure 1C). Rod markers are maintained while cone markers are absent from adult animals (Figure 4). The mice also exhibit normal optokinetic responses to rod stimulation and absent optokinetic responses to cone stimulation (Figure 4).","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/18824093","type":"dc:BibliographicResource","dc:abstract":"In mammals, the blockade of the phototransduction cascade causes loss of vision and, in some cases, degeneration of photoreceptors. However, the molecular mechanisms that link phototransduction with photoreceptor degeneration remain to be elucidated. Here, we report that a mutation in the gene encoding a central effector of the phototransduction cascade, cGMP phosphodiesterase 6alpha'-subunit (PDE6alpha'), affects not only the vision but also the survival of cone photoreceptors in zebrafish. We isolated a zebrafish mutant, called eclipse (els), which shows no visual behavior such as optokinetic response (OKR). The cloning of the els mutant gene revealed that a missense mutation occurred in the pde6alpha' gene, resulting in a change in a conserved amino acid. The PDE6 expressed in rod photoreceptors is a heterotetramer comprising two closely related similar hydrolytic alpha and beta subunits and two identical inhibitory gamma subunits, while the PDE6 expressed in cone photoreceptors consists of two homodimers of alpha' subunits, each with gamma subunits. The els mutant displays no visual response to bright light, where cones are active, but shows relatively normal OKR to dim light, where only rods function, suggesting that only the cone-specific phototransduction pathway is disrupted in the els mutant. Furthermore, in the els mutant, cones are selectively eliminated but rods are retained at the adult stage, suggesting that cones undergo a progressive degeneration in the els mutant retinas. Taken together, these data suggest that PDE6alpha' activity is important for the survival of cones in zebrafish.","dc:creator":"Nishiwaki Y","dc:date":"2008","dc:title":"Mutation of cGMP phosphodiesterase 6alpha'-subunit gene causes progressive degeneration of cone photoreceptors in zebrafish."},"rdfs:label":"The els zebrafish mutant is homozygous for a PDE6C variant."}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2,"dc:description":"The model recapitulates the cone loss and other cellular features of the human patients, as well as inability to respond to stimuli under light conditions."},{"id":"cggv:3355b893-f259-45f6-a956-a5875333225c","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:e6f345e2-4446-4477-aff8-f8f668f4b869","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"This is a naturally occurring mouse model with lack of light-adapted ERG responses and normal dark-adapted ERG responses (Figure 1). The mice also exhibit rapid and progressive loss of cone photoreceptors from retinal sections (Figure 2). These features match the underlying cone-specific phenotypes observed in the human patients.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/19887631","type":"dc:BibliographicResource","dc:abstract":"Retinal cone photoreceptors mediate fine visual acuity, daylight vision, and color vision. Congenital hereditary conditions in which there is a lack of cone function in humans cause achromatopsia, an autosomal recessive trait, characterized by low vision, photophobia, and lack of color discrimination. Herein we report the identification of mutations in the PDE6C gene encoding the catalytic subunit of the cone photoreceptor phosphodiesterase as a cause of autosomal recessive achromatopsia. Moreover, we show that the spontaneous mouse mutant cpfl1 that features a lack of cone function and rapid degeneration of the cone photoreceptors represents a homologous mouse model for PDE6C associated achromatopsia.","dc:creator":"Chang B","dc:date":"2009","dc:title":"A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene."},"rdfs:label":"The Cpfl1 mouse harbors LOF variants in the Pde6c locus."}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1.5,"dc:description":"The mouse features match the underlying cone-specific phenotypes observed in the human patients, but testing for some of the resulting visual issues have not been described."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5.5},{"id":"cggv:73ed48ac-bdd6-4608-953d-773da6ade759_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:e037d348-529e-45df-bb2c-bb2c0424ea7d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:e037d348-529e-45df-bb2c-bb2c0424ea7d","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":12,"allele":[{"id":"cggv:61b73804-8dae-4356-92c0-29d93e662b02","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.633G>C (p.Glu211Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119901"}},{"id":"cggv:4e9d7567-f3c5-4078-959a-251866f32758","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.1363A>G (p.Met455Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119900"}}],"detectionMethod":"Affected and unaffected family members were subjected to Sanger sequencing-based screening of the 22 exons and flanking regions of PDE6C.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The proband and affected family member were previously diagnosed with complete achromatopsia. The proband had onset by age 12 years.","phenotypes":["obo:HP_0000613","obo:HP_0000551","obo:HP_0030465","obo:HP_0000639","obo:HP_0031624","obo:HP_0030825","obo:HP_0030534"],"previousTesting":false,"previousTestingDescription":" Previous testing in this family appears to have been limited to phenotype analysis.","sex":"Female","variant":[{"id":"cggv:2fd45a98-283c-41ff-9b93-ee35717ce10e_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:61b73804-8dae-4356-92c0-29d93e662b02"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19615668"},{"id":"cggv:643ffea1-b086-4536-a90c-76597a005bff_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:4e9d7567-f3c5-4078-959a-251866f32758"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19615668"}],"rdfs:label":"Thiadens_2009_Family_D_Proband_DII-1"},{"id":"cggv:2fd45a98-283c-41ff-9b93-ee35717ce10e","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:2fd45a98-283c-41ff-9b93-ee35717ce10e_variant_evidence_item"}],"strengthScore":0.25,"dc:description":"NM_006204.4(PDE6C):c.633G>C (p.Glu211Asp) is not a missense variant but rather a substitution of the last base pair of exon 2 that is predicted to disrupt the splice donor site. Up-scoring has been performed for the variant type, while down-scoring has been performed due to the limitations of the genotyping method."},{"id":"cggv:643ffea1-b086-4536-a90c-76597a005bff","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:643ffea1-b086-4536-a90c-76597a005bff_variant_evidence_item"}],"strengthScore":0.1,"dc:description":"NM_006204.4(PDE6C):c.1363A>G (p.Met455Val) is a missense variant that does not have experimental evidence of a functional effect on the protein product."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:e2ad1a59-457b-434a-ad9d-d8f02a5ae6a4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:e2ad1a59-457b-434a-ad9d-d8f02a5ae6a4","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":17,"allele":{"id":"cggv:a77e4f4c-b263-452d-a554-38f3ef13169b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.1579C>T (p.Arg527Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA211539823"}},"detectionMethod":"The proband has been genotyped by Sanger sequencing of CNGB3, CNGA3, GNAT2, and PDE6C, as well as next-generation sequencing of PDE6C and possibly other loci.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"The proband has been previously diagnosed with achromatopsia.","phenotypes":["obo:HP_0000613","obo:HP_0030465","obo:HP_0000639"],"previousTesting":true,"previousTestingDescription":"The patient was previously genotyped by Sanger sequencing of CNGB3, CNGA3, and GNAT2.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"cggv:e662f390-8f53-42a3-b462-6d5e46eaa3f4_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a77e4f4c-b263-452d-a554-38f3ef13169b"},"alleleOrigin":{"id":"obo:GENO_0000877"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/30080950","type":"dc:BibliographicResource","dc:abstract":"Biallelic PDE6C mutations are a known cause for rod monochromacy, better known as autosomal recessive achromatopsia (ACHM), and early-onset cone photoreceptor dysfunction. PDE6C encodes the catalytic Î±'-subunit of the cone photoreceptor phosphodiesterase, thereby constituting an essential part of the phototransduction cascade. Here, we present the results of a study comprising 176 genetically preselected patients who remained unsolved after Sanger sequencing of the most frequent genes accounting for ACHM, and were subsequently screened for exonic and splice site variants in PDE6C applying a targeted next generation sequencing approach. We were able to identify potentially pathogenic biallelic variants in 15 index cases. The mutation spectrum comprises 18 different alleles, 15 of which are novel. Our study significantly contributes to the mutation spectrum of PDE6C and allows for a realistic estimate of the prevalence of PDE6C mutations in ACHM since our entire ACHM cohort comprises 1,074 independent families.","dc:creator":"Weisschuh N","dc:date":"2018","dc:title":"Mutations in the gene PDE6C encoding the catalytic subunit of the cone photoreceptor phosphodiesterase in patients with achromatopsia."}},"rdfs:label":"Weisschuh_2018_Patient_3"},{"id":"cggv:e662f390-8f53-42a3-b462-6d5e46eaa3f4","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:e662f390-8f53-42a3-b462-6d5e46eaa3f4_variant_evidence_item"}],"strengthScore":1,"dc:description":"NM_006204.4(PDE6C):c.1579C>T (p.Arg527Ter) is a nonsense variant in exon 12 of 22 that is predicted to trigger nonsense mediated decay or to at least truncate the C-terminal 39% of the protein product. The variant has been down-scored for homozygosity and the limitations of the genotyping method."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:909d02d2-ab6e-492e-9f90-fb70fecbd28c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:909d02d2-ab6e-492e-9f90-fb70fecbd28c","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":35,"allele":[{"id":"cggv:c9624e89-7f65-4653-beee-fe7b415b547d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.775C>T (p.Arg259Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5609938"}},{"id":"cggv:6bf8affe-bf80-43fd-b80b-704e0380fdc1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.78del (p.Lys27SerfsTer27)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658823170"}}],"detectionMethod":"The proband has been genotyped by Sanger sequencing of CNGB3, CNGA3, GNAT2, and PDE6C, as well as next-generation sequencing of PDE6C and possibly other loci.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"The proband has been previously diagnosed with achromatopsia.","phenotypes":["obo:HP_0000551","obo:HP_0030534","obo:HP_0000613","obo:HP_0030465"],"previousTesting":true,"previousTestingDescription":"The patient was previously genotyped by Sanger sequencing of CNGB3, CNGA3, and GNAT2.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":[{"id":"cggv:37bfff9e-40d4-43a7-8b10-4099128621b3_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:6bf8affe-bf80-43fd-b80b-704e0380fdc1"},"alleleOrigin":{"id":"obo:GENO_0000877"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30080950"},{"id":"cggv:d304d8c6-4429-464f-8469-6c4a784731b4_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c9624e89-7f65-4653-beee-fe7b415b547d"},"alleleOrigin":{"id":"obo:GENO_0000877"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30080950"}],"rdfs:label":"Weisschuh_2018_Patient_8"},{"id":"cggv:37bfff9e-40d4-43a7-8b10-4099128621b3","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:37bfff9e-40d4-43a7-8b10-4099128621b3_variant_evidence_item"}],"strengthScore":1.25,"dc:description":"NM_006204.4(PDE6C):c.78del (p.Lys27fs) is a frameshift variant in exon 1 of 12 that is predicted to trigger nonsense mediated decay or to at least truncate the C-terminal 97% of the protein product."},{"id":"cggv:d304d8c6-4429-464f-8469-6c4a784731b4","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:d304d8c6-4429-464f-8469-6c4a784731b4_variant_evidence_item"}],"strengthScore":1.25,"dc:description":"NM_006204.4(PDE6C):c.775C>T (p.Arg259Ter) is a nonsense variant in exon 4 of 22 that is predicted to trigger nonsense mediated decay or to at least truncate the C-terminal 70% of the protein product."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:abc26307-9894-4a76-8379-c5a83014b441_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:abc26307-9894-4a76-8379-c5a83014b441","type":"Proband","allele":[{"id":"cggv:6aafa968-05da-485a-b8f4-4ab6f786da1b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.1805A>T (p.His602Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119905"}},{"id":"cggv:9abeb8f3-9986-437b-bd43-7d08d06b880c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.2368G>A (p.Glu790Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119903"}}],"detectionMethod":"*CNGA3*, *GNGB3*, and *GNAT2* were previously screened / known not to harbor causal variants for achromatopsia. The family members were then subjected to Sanger sequencing of the 22 exons and flanking regions of *PDE6C*.","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"The proband and an affected family member were previously diagnosed with achromatopsia.","phenotypes":"obo:HP_0011516","previousTesting":true,"previousTestingDescription":"Affected and unaffected family members were initially subjected to genotyping of the *CNGA3*, *GNGB3*, and *GNAT2* loci, confirming absence of causal variants in these known achromatopsia-related genes.","sex":"Male","variant":[{"id":"cggv:0d3cee88-bb8a-4e91-a510-b8e3ab7e5cbb_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:9abeb8f3-9986-437b-bd43-7d08d06b880c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19887631"},{"id":"cggv:cd3b7870-a1b8-4e25-8f4d-58731a1a04ae_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:6aafa968-05da-485a-b8f4-4ab6f786da1b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19887631"}],"rdfs:label":"Chang_2009_Family_CHRO102_Proband_II:1"},{"id":"cggv:cd3b7870-a1b8-4e25-8f4d-58731a1a04ae","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:cd3b7870-a1b8-4e25-8f4d-58731a1a04ae_variant_evidence_item"},{"id":"cggv:cd3b7870-a1b8-4e25-8f4d-58731a1a04ae_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"NM_006204.4(PDE6C):c.1805A>T (p.His602Leu) is a missense variant that has been expressed in Sf9 cells and subjected to an enzymatic assay showing approximately 90% loss of activity (Figure 5)."}],"strengthScore":1,"dc:description":"The variant has been up-scored for evidence of a deleterious impact at the enzymatic level."},{"id":"cggv:0d3cee88-bb8a-4e91-a510-b8e3ab7e5cbb","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:0d3cee88-bb8a-4e91-a510-b8e3ab7e5cbb_variant_evidence_item"},{"id":"cggv:0d3cee88-bb8a-4e91-a510-b8e3ab7e5cbb_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"NM_006204.4(PDE6C):c.2368G>A (p.Glu790Lys) acts in part as an exonic splicing variant that has been expressed in COS7 cells and triggers 40% of transcripts to skip exon 21 and undergo frameshift (Figure S5C). The remaining transcripts encode a missense variant that has been expressed in Sf9 cells and subjected to an enzymatic assay showing approximately 40% loss of activity (Figure 5)."}],"strengthScore":0.5,"dc:description":"The variant has been up-scored for experimental evidence of an impact on the gene product."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:71dbb9d6-995a-41dd-ba2e-0b175ea41002_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:71dbb9d6-995a-41dd-ba2e-0b175ea41002","type":"Proband","allele":{"id":"cggv:aa2118e2-b60b-4822-a216-cf3f51b25f45","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.1682dup (p.Tyr561Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA212909"}},"detectionMethod":"*CNGA3*, *GNGB3*, and *GNAT2* were previously screened / known not to harbor causal variants for achromatopsia. The family members were then subjected to Sanger sequencing of the 22 exons and flanking regions of *PDE6C*.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The proband was previously diagnosed with achromatopsia.","phenotypes":"obo:HP_0011516","previousTesting":true,"previousTestingDescription":"The proband and his family members were initially subjected to genotyping of the *CNGA3*, *GNGB3*, and *GNAT2* loci, confirming absence of causal variants in these known achromatopsia-related genes.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:54b77cc8-43a0-492f-a660-d4b71fc88bd8_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:aa2118e2-b60b-4822-a216-cf3f51b25f45"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19887631"},"rdfs:label":"Chang_2009_Family_CHRO572_Proband_II:1"},{"id":"cggv:54b77cc8-43a0-492f-a660-d4b71fc88bd8","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:54b77cc8-43a0-492f-a660-d4b71fc88bd8_variant_evidence_item"},{"id":"cggv:54b77cc8-43a0-492f-a660-d4b71fc88bd8_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"NM_006204.4(PDE6C):c.1682dup (p.Tyr561Ter) is a nonsense variant in exon 13 of 22 and is predicted to trigger nonsense-mediated decay or to at least truncate the C-terminal 35% of the protein product. "}],"strengthScore":1,"dc:description":"Down-scoring has been performed due to homozygosity and the limitations of the genotyping method."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:f5a7e441-2ed3-4ac9-8f91-31016e465901_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:f5a7e441-2ed3-4ac9-8f91-31016e465901","type":"Proband","allele":[{"id":"cggv:125ce1ee-3bd3-4075-9b00-77a77d889aaf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.1483-2A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA212908"}},{"id":"cggv:aa213a7f-fa52-4f5b-b1fa-ba6f7fe4bf8a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.481-12T>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA212907"}}],"detectionMethod":"*CNGA3*, *GNGB3*, and *GNAT2* were previously screened / known not to harbor causal variants for achromatopsia. The family members were then subjected to Sanger sequencing of the 22 exons and flanking regions of *PDE6C*.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The proband and an affected family member were previously diagnosed with achromatopsia.","phenotypes":["obo:HP_0003593","obo:HP_0007401","obo:HP_0000551","obo:HP_0030465","obo:HP_0000613","obo:HP_0030479","obo:HP_0000603","obo:HP_0001141","obo:HP_0011003"],"previousTesting":true,"previousTestingDescription":"Affected and unaffected family members were initially subjected to genotyping of the *CNGA3*, *GNGB3*, and *GNAT2* loci, confirming absence of causal variants in these known achromatopsia-related genes.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"cggv:b5aaf9d8-74e0-434f-84b7-47ff74d454c1_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:125ce1ee-3bd3-4075-9b00-77a77d889aaf"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19887631"},{"id":"cggv:06afc5cf-290d-47d9-b508-010eec4d669b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:aa213a7f-fa52-4f5b-b1fa-ba6f7fe4bf8a"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19887631"}],"rdfs:label":"Chang_2009_Family_CHRO9_Proband_II:3"},{"id":"cggv:06afc5cf-290d-47d9-b508-010eec4d669b","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:06afc5cf-290d-47d9-b508-010eec4d669b_variant_evidence_item"},{"id":"cggv:06afc5cf-290d-47d9-b508-010eec4d669b_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"NM_006204.4(PDE6C):c.481-12T>A is an intronic variant that has been subjected to a mini-gene assay in COS7 cells and triggers a fully penetrant splicing defect (use of a cryptic splice site 10 nucleotides upstream, resulting in a frameshift encoding p.Asn161fsX169, Figure S5A)."}],"strengthScore":1,"dc:description":"Up-scoring has been performed for splicing evidence that the variant is a complete null."},{"id":"cggv:b5aaf9d8-74e0-434f-84b7-47ff74d454c1","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:b5aaf9d8-74e0-434f-84b7-47ff74d454c1_variant_evidence_item"},{"id":"cggv:b5aaf9d8-74e0-434f-84b7-47ff74d454c1_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"NM_006204.4(PDE6C):c.1483-2A>G is a canonical splice site variant that has been subjected to a mini-gene assay in COS7 cells and triggers a fully penetrant splicing defect (exon 12 skipping, resulting in an in-frame deletion encoding p.495_543del49, Figure S5B)."}],"strengthScore":1,"dc:description":"Up-scoring has been performed for splicing evidence that the variant is a complete null."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:73ed48ac-bdd6-4608-953d-773da6ade759_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:149a657c-e56b-436c-8c8d-771b6d0ad970_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:149a657c-e56b-436c-8c8d-771b6d0ad970","type":"Proband","allele":[{"id":"cggv:a9dffa57-d5bd-4844-912b-5f04851c6f1e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.826C>T (p.Arg276Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119907"}},{"id":"cggv:de6cb250-54e4-4fcc-b3c4-2c0caf571d38","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.2457T>A (p.Tyr819Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119909"}}],"detectionMethod":"*CNGA3*, *GNGB3*, and *GNAT2* were previously screened / known not to harbor causal variants for achromatopsia. The family members were then subjected to Sanger sequencing of the 22 exons and flanking regions of *PDE6C*.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The proband was previously diagnosed with achromatopsia.","phenotypes":"obo:HP_0011516","previousTesting":true,"previousTestingDescription":"The proband and his parents were initially subjected to genotyping of the *CNGA3*, *GNGB3*, and *GNAT2* loci, confirming absence of causal variants in these known achromatopsia-related genes.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"cggv:6aa9aaf2-c619-40d9-a9f2-3a56cd8f8023_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:de6cb250-54e4-4fcc-b3c4-2c0caf571d38"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19887631"},{"id":"cggv:78eefd67-84c8-4284-aaa0-e6fe9c903703_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a9dffa57-d5bd-4844-912b-5f04851c6f1e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19887631"}],"rdfs:label":"Chang_2009_Family_CHRO287_Proband_II:1"},{"id":"cggv:78eefd67-84c8-4284-aaa0-e6fe9c903703","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:78eefd67-84c8-4284-aaa0-e6fe9c903703_variant_evidence_item"},{"id":"cggv:78eefd67-84c8-4284-aaa0-e6fe9c903703_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"No","dc:description":"NM_006204.4(PDE6C):c.826C>T (p.Arg276Ter) is a nonsense variant in exon 4 of 22 and is predicted to trigger nonsense-mediated decay or to at least truncate the C-terminal 68% of the protein product."}],"strengthScore":1.5,"dc:description":"The variant has been up-scored for its predicted effect on the protein product."},{"id":"cggv:6aa9aaf2-c619-40d9-a9f2-3a56cd8f8023","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:6aa9aaf2-c619-40d9-a9f2-3a56cd8f8023_variant_evidence_item"},{"id":"cggv:6aa9aaf2-c619-40d9-a9f2-3a56cd8f8023_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"No","dc:description":"NM_006204.4(PDE6C):c.2457T>A (p.Tyr819Ter) is a nonsense variant in exon 21 of 22 and is predicted to trigger nonsense-mediated decay or to at least truncate the C-terminal 5% of the protein product."}],"strengthScore":1.5,"dc:description":"The variant has been up-scored for its predicted effect on the protein product."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:b7ea0e4f-d006-4a68-8cbb-b3769d714dd2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:b7ea0e4f-d006-4a68-8cbb-b3769d714dd2","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":6,"allele":{"id":"cggv:140e35db-b3be-4340-91a8-c56e78824dd3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006204.4(PDE6C):c.85C>T (p.Arg29Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340825"}},"detectionMethod":"Affected and unaffected family members were initially subjected to homozygosity mapping based on Affymetrix GeneChIP SNP analysis, identifying an 11-Mb region of homozygosity shared with another unrelated family. The clear candidate gene, PDE6C, was then subjected to Sanger sequencing-based screening of the 22 exons and flanking regions.","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"The proband and affected family member were previously diagnosed with early onset autosomal recessive cone dystrophy. The proband had onset by age 6 years.","phenotypes":["obo:HP_0000551","obo:HP_0030825","obo:HP_0007703","obo:HP_0000639","obo:HP_0030465","obo:HP_0011003","obo:HP_0000613","obo:HP_0030534"],"previousTesting":true,"previousTestingDescription":"Affected and unaffected family members were initially subjected to homozygosity mapping based on Affymetrix GeneChIP SNP analysis, identifying an 11-Mb region of homozygosity shared with another unrelated family.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:2b112de2-fed0-47bd-89be-24732b86b1e1_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:140e35db-b3be-4340-91a8-c56e78824dd3"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19615668"},"rdfs:label":"Thiadens_2009_Family_A_Proband_AII-2"},{"id":"cggv:2b112de2-fed0-47bd-89be-24732b86b1e1","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:2b112de2-fed0-47bd-89be-24732b86b1e1_variant_evidence_item"}],"strengthScore":0.1,"dc:description":"NM_006204.4(PDE6C):c.85C>T (p.Arg29Trp) is a missense variant that does not have experimental evidence of a functional effect on the protein product. However, it has been reported in similarly affected individuals in other studies (PMID: 21127010, PMID: 30080950)."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":7377,"specifiedBy":"GeneValidityCriteria10","strengthScore":17.5,"subject":{"id":"cggv:d9e21ce7-1dc9-4a71-a5ce-5fb8d204d012","type":"GeneValidityProposition","disease":"obo:MONDO_0019118","gene":"hgnc:8787","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"The *PDE6C* gene was first reported in relation to cone dystrophy with an autosomal recessive mode of inheritance in 2009 (Thiadens et al., PMID: 19615668). Affected individuals with biallelic causal variants in *PDE6C* have since been identified in a number of subsequent publications. Phenotypes generally occur with congenital or early childhood onset and include severe color vision defects, progressive loss of visual acuity over the course of decades, reduced or absent cone/photopic ERG responses, normal rod/scotopic ERG responses, photophobia, myopia, and/or nystagmus. At least one patient has been reported with central scotoma and macular retinal pigment epithelium atrophy (PMID: 19887631). These cases with causal variants in *PDE6C* are specifically described as cone dystrophy 4 or achromatopsia 5 (MIM#: 613093), depending on the extent of disease progression at the time of diagnosis. Additional case reports have suggested an expanded spectrum of disease that includes phenotypes consistent with cone-rod dystrophy, including electroretinograms with decreased amplitude on both phototopic and scotopic waveforms and mild/moderate constrictions to visual field (PMID: 33001157). Because these diagnoses are considered part of the same phenotypic spectrum, this curation has evaluated a combination of cases under the disease term PDE6C-related retinopathy.\n\nThirteen suspected deleterious variants in *PDE6C* were scored as part of this curation (five nonsense, 1 frameshift, four missense, and three affecting splicing). These variants have been collectively reported in eight probands in three publications (PMID: 19615668, PMID: 19887631, PMID: 30080950). Three probands were homozygous for the variant of interest, but were not reported to be members of consanguineous families. The mechanism of pathogenicity appears to be loss of function in *PDE6C*, characterized in at least some cases by variants predicted to trigger the absence of the gene product or loss of the majority of its enzymatic activity. Additional genetic evidence was available (PMID: 32306724, PMID: 33001157, PMID: 37433860) but not included in this curation as the maximum scoring for this evidence type had already been reached.\n\nThis gene-disease association is also supported by evidence that *PDE6C* is highly expressed specifically in retinal tissues (PMID: 30239781). Biochemical data show that *PDE6C* encodes a cGMP phosphodiesterase that is part of the phototransduction cascade and is associated specifically with cone photoreceptor cells, consistent with the cone-specific dysfunction observed in the human patients (PMID: 19801642). This biochemical function parallels that of the *PDE6A* gene, which encodes a rod-specific cGMP phosphodiesterase and harbors loss-of-function variants associated with retinal dystrophy (PMID: 7493036). Naturally occurring zebrafish, mice, and rhesus macaque models harboring biallelic loss-of-function variants in the gene orthologous to *PDE6C* recapitulate many of the features of the human patients such as reduced visual acuity, particularly under normal lighting conditions, lack of light-adapted ERG responses, and normal dark-adapted ERG responses (PMID: 18824093, PMID: 19887631, PMID: 30667376). These models also collectively exhibit progressive thinning of the outer nuclear layer and photoreceptor outer segments within the macula, caused by rapid and progressive loss of cone photoreceptors (PMID: 18824093, PMID: 19887631, PMID: 30667376).\n\nIn summary, *PDE6C* is definitively associated with PDE6C-related retinopathy. This has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a definitive classification. This classification has been approved by the ClinGen Retina GCEP on November 2nd, 2023 (SOP Version 10).","dc:isVersionOf":{"id":"cggv:73ed48ac-bdd6-4608-953d-773da6ade759"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}